NCT04203303 Implications of the Human Microbiota for Health and Disease
| NCT ID | NCT04203303 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Human Microbiota |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2019-10-03 |
| Primary Completion | 2030-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2019-10-03 with a primary completion date of 2030-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to advance the understanding of human health and disease as it relates to environmental factors that may affect intestinal and non-intestinal microbiota.
Eligibility Criteria
Inclusion Criteria: * Age 18 years of age or older * Able to provide informed consent Exclusion Criteria: * None
Contact & Investigator
Virend Somers, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT04203303 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Human Microbiota. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04203303 currently recruiting?
Yes, NCT04203303 is actively recruiting participants. Contact the research team at Karim.Shahid@mayo.edu for enrollment information.
Where is the NCT04203303 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT04203303 clinical trial?
NCT04203303 is sponsored by Mayo Clinic. The principal investigator is Virend Somers, MD at Mayo Clinic. The trial plans to enroll 5,000 participants.